Scottish HTA Okays Neuroblastoma Ultra Orphan Qarziba
Executive Summary
The Scottish Medicines Consortium has recommended EUSA’s ultra-orphan neuroblastoma treatment Qarziba.
You may also be interested in...
Scotland Launches New ‘Ultra-Orphan’ Assessment Pathway
The Scottish government is launching its new pathway for the assessment of “ultra-orphan” medicines by the HTA body, the Scottish Medicines Consortium, in an effort to speed up access to medicines for patients with very rare diseases
New Standard Of Care Secures EU OK For Neuroblastoma Drug
Changes in the EU in the standard of care for high-risk neuroblastoma has resulted in EUSA Pharma’s monoclonal antibody being approved by the European Commission under exceptional circumstances.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.